Pinnacle Summer Investments’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Pinnacle Summer Investments’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$0	Hold	28	–	–	﹤0.01%	1088
2015 Q3	$0	Buy	+28	New	+$574	﹤0.01%	1067
2014 Q4	–	Sell	-28	Closed	-$304	–	1116
2014 Q3	$0	Hold	28	–	–	﹤0.01%	1111
2014 Q2	$1K	Hold	28	–	–	﹤0.01%	984
2014 Q1	$0	Hold	28	–	–	﹤0.01%	1027
2013 Q4	$0	Buy	+28	New	+$313	﹤0.01%	1021

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Pinnacle Summer Investments's CASC Position: Q4 2015 in Review

Pinnacle Summer Investments held its Cascadian Therapeutics, Inc. (CASC) position steady in Q4 2015 at 28 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Pinnacle Summer Investments first reported a position in CASC in Q4 2013 and has held it in 6 quarters since. The position peaked at $1K in Q2 2014. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

Pinnacle Summer Investments held 28 shares of Cascadian Therapeutics, Inc. worth $0 as of Q4 2015.
Pinnacle Summer Investments left its Cascadian Therapeutics, Inc. share count unchanged in Q4 2015.
Cascadian Therapeutics, Inc. made up ﹤0.01% of Pinnacle Summer Investments's portfolio in Q4 2015, its #1088 holding.
Pinnacle Summer Investments first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and has held it in 6 quarters since.
Pinnacle Summer Investments's Cascadian Therapeutics, Inc. position peaked at $1K in Q2 2014.
93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Pinnacle Summer Investments's 13F filing for Q4 2015, filed 16 Feb 2016.